title: Protective effect of resolvin E1 on the development of asthmatic airway inflammation.
abstract: Resolvin E1 (RvE1) is an anti-inflammatory lipid mediator derived from the omega-3 fatty acid eicosapentaenoic acid (EPA), and strongly acts in the resolution of inflammation. We previously reported that RvE1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. In the present study, to elucidate the effects of RvE1 on the development of asthmatic airway inflammation, we investigated whether RvE1 acts on different phases of an OVA-sensitized and -challenged mouse model of asthma. RvE1 treatments at the time of either OVA sensitization or at the time of OVA challenge were investigated and compared with RvE1 treatments at the time of both OVA sensitization and challenge. After RvE1 was administered to mice intraperitoneally at the time of both OVA sensitization and challenge, there were decreases in airway eosinophil and lymphocyte recruitment, as well as a reduction in Th2 cytokine and airway hyperresponsiveness. RvE1 treatment at the time of either OVA sensitization or challenge also improved AHR and airway inflammation. Our results suggest that RvE1 acts on several phases of asthmatic inflammation and may have anti-inflammatory effects on various cell types.
authors: Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
authors: Haruka
authors: H
authors: Aoki
authors: Takeshi
authors: T
authors: Hisada
authors: Tamotsu
authors: T
authors: Ishizuka
authors: Mitsuyoshi
authors: M
authors: Utsugi
authors: Akihiro
authors: A
authors: Ono
authors: Yasuhiko
authors: Y
authors: Koga
authors: Noriaki
authors: N
authors: Sunaga
authors: Takashi
authors: T
authors: Nakakura
authors: Fumikazu
authors: F
authors: Okajima
authors: Kunio
authors: K
authors: Dobashi
authors: Masatomo
authors: M
authors: Mori
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D016535:Bronchial Hyperreactivity / Q000188:drug therapy / Q000517:prevention & control; D004195:Disease Models, Animal; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D011014:Pneumonia / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control
chemical_list: D010047:Ovalbumin; D015118:Eicosapentaenoic Acid; C499823:5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid